Updated on 6 January 2014
Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product
Singapore: Astellas Pharma and ClearPath Development Company have announced a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases.
The announcement specified that the partnership was established to support Astellas' goal of building a global vaccine franchise and launched its first company, RSV Corporation (RSVC), in December 2013.
The report also added that Astellas will fund RSVC's development of a virosome vaccine technology, licensed from Mymetics Corporation, for respiratory syncytial virus (RSV) through completion of a Phase 2b human proof-of-concept study.
Based on the strategic partnership, Astellas received exclusive rights to acquire RSVC as well as further develop and commercialize the vaccine product.
"This partnership highlights our commitment to build a global vaccine business and represents a highly efficient model for bringing innovative vaccines to market. It is also a unique opportunity for Astellas to utilize external cutting edge science and technology to enhance our ability to generate innovative drugs, as part of the ‘Reshaping Research Framework' program announced in May, 2013," said Kenji Yasukawa, Senior Vice President and Chief Strategy Officer, Astellas.